Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Income from Continuing Operations (2024 - 2025)

Kairos Pharma's Income from Continuing Operations history spans 2 years, with the latest figure at 1422000.0 for Q2 2025.

  • For Q2 2025, Income from Continuing Operations fell 507.69% year-over-year to 1422000.0; the TTM value through Jun 2025 reached 5050000.0, changed N/A, while the annual FY2025 figure was 5447000.0, 129.06% down from the prior year.
  • Income from Continuing Operations reached 1422000.0 in Q2 2025 per KAPA's latest filing, down from 1262000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 234000.0 in Q2 2024 to a low of 1446000.0 in Q4 2024.